Greg Thurber

Professor, Chemical & Biomedical Engineering University of Michigan

Greg Thurber PhD. is a Professor of Chemical and Biomedical Engineering at the University of Michigan. The Thurber lab uses in vivo microscopy and mathematical simulations to develop quantitative and predictive simulations of drug and imaging agent distribution. The core theory is used in multiple applications, including pharmacokinetic and pharmacodynamic models for cancer therapy and chemoprevention and imaging agent development for screening, diagnosis, intraoperative imaging, and treatment monitoring. To this end, we are exploring a range of potential drug and imaging molecules, from small compounds to peptides, and all the way up to antibodies to better understand their targeting and distribution properties.

Seminars

Monday 8th March 2027
Antibody Design for Effective ADCs: The Multiple Impacts of Fc Engineering
  • Antibody design for ADCs include enhanced, wild type, and silent Fc domains
  • Fc interactions can have multiple effects on ADC efficacy and toxicity
  • We will cover how to make the best selection based on the payload, antibody, and tumour type
Tuesday 9th March 2027
Panel Discussion: Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
5:00 pm
  • Debating the optimal chemical and biological properties of next-generation payload and linker combinations
  • Exploring the novelty of dual-payload ADCs and their potential to overcome resistance mechanisms associated with traditional ADCs
  • Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
Thursday 11th March 2027
Accelerating ADC Model Simulation with the Power of Artificial Intelligence & Machine Learning
9:00 am

This workshop will explore how artificial intelligence and machine learning are transforming ADC target identification and screening, payload optimisation, and toxicity prediction within model systems. Discuss practical implementation challenges, data requirements, and regulatory considerations for AI-driven approaches.

Key Questions:

  • How can AI improve target risk assessment and reduce preclinical attrition?
  • What data sets are required to build predictive toxicity models?
  • How do we validate AI algorithms for regulatory data packages?
  • What are the limitations of current AI approaches in ADC development?
Headshot Of Greg Thurber